Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02959658

Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis — FUMAPMS  

Primary Progressive Multiple Sclerosis Clinical Trial

Official title:
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis

Clinical Trial Summary

This study aims to evaluate safety and efficacy of dimethyl fumarate treatment in patients with primary progressive multiple sclerosis (PPMS). Half of the patients will receive dimethyl fumarate and the other half will receive placebo.

Clinical Trial Description

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system and is presumed to be caused by T cell-mediated autoimmune processes. PPMS has no registered treatment options only symptomatic treatment exists. Progressive forms of MS are characterized clinically by gradual symptom development with or without superimposed relapses. Fumarates have long been known to have disease-attenuating effects in psoriasis. They have been in routine use in dermatology in Germany for several decades. Dimethyl fumarate has the interesting property of combining immunological effects, at least partly mediated by interference with nuclear factor kappa B and other transcription factors, and also anti-oxidative and neuroprotective effects mediated by activation of the transcription factor Nuclear factor (erythroid-derived 2)-Related Factor 2 (NRF2). Dimethyl fumarate is currently approved for treatment of relapsing-remitting MS by the European medicines Agency in a dose of 240 mg twice per day. Neurofilament light chain (NFL) is a treatment responsive biomarker of neuronal and axonal death when appearing in the cerebrospinal fluid (CSF) and it has been associated with long-term prognosis in MS. The concentration is often elevated in progressive MS patients. Treatment effect is measured by measuring changes in neurofilament light chain concentration over the course of 48 weeks of treatment with either active drug or placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02959658
Study type Interventional
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase Phase 2
Start date December 2016
Completion date December 9, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Recruiting NCT02273635 - Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Phase 1/Phase 2
Withdrawn NCT05029609 - Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS Phase 1
Terminated NCT03283826 - Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Phase 1/Phase 2
Active, not recruiting NCT05974839 - Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
Active, not recruiting NCT05974852 - Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Recruiting NCT04977622 - Gray Matter Demyelination in Primary Progressive MS at 7T
Recruiting NCT05893225 - Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration Phase 2
Completed NCT03094364 - Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis N/A
Completed NCT02253264 - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Phase 1
Recruiting NCT03691077 - Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 Phase 3
Completed NCT00950248 - Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) Phase 1/Phase 2
Active, not recruiting NCT05232825 - A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Phase 3
Recruiting NCT05229861 - The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS N/A
Completed NCT01077466 - Natalizumab Treatment of Progressive Multiple Sclerosis Phase 2
Completed NCT01854359 - Idebenone for Primary Progressive Multiple Sclerosis Phase 1/Phase 2
Completed NCT03493841 - Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis Phase 1
Active, not recruiting NCT03562975 - Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Completed NCT00731692 - FTY720 in Patients With Primary Progressive Multiple Sclerosis Phase 3
Recruiting NCT04943289 - Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis Phase 1